Macrophage activation syndrome

[1]  B. Vaidyanathan,et al.  Systemic onset juvenile idiopathic arthritis with macrophage activation syndrome misdiagnosed as Kawasaki disease: case report and literature review , 2013, Rheumatology International.

[2]  A. Rawat,et al.  Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India , 2012, Rheumatology International.

[3]  R. Cron,et al.  Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment , 2012, Genes and Immunity.

[4]  A. Martini,et al.  Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis , 2011, Pediatric Rheumatology Online Journal.

[5]  M. Jordan,et al.  Perforin is a critical physiologic regulator of T-cell activation. , 2011, Blood.

[6]  G. Koretzky,et al.  Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. , 2011, The Journal of clinical investigation.

[7]  I. Koné-Paut,et al.  Macrophage activation syndrome revealing familial Mediterranean fever , 2011, Arthritis care & research.

[8]  A. Martini,et al.  An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis , 2011, The Journal of Rheumatology.

[9]  Hidenori Sato,et al.  Association of IRF5 Polymorphisms with Susceptibility to Macrophage Activation Syndrome in Patients with Juvenile Idiopathic Arthritis , 2011, The Journal of Rheumatology.

[10]  E. Alexeeva,et al.  Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis , 2011, Clinical Rheumatology.

[11]  Sharath Kumar,et al.  Posterior Reversible Encephalopathy Syndrome (PRES/RPLS) During Pulse Steroid Therapy in Macrophage Activation Syndrome , 2011, Indian journal of pediatrics.

[12]  A. Mimori,et al.  Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome , 2011, Modern rheumatology.

[13]  Andrew I. Shulman,et al.  Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. , 2011, Arthritis and rheumatism.

[14]  R. Cron,et al.  Combination Therapy of Abatacept and Anakinra in Children with Refractory Systemic Juvenile Idiopathic Arthritis: A Retrospective Case Series , 2011, The Journal of Rheumatology.

[15]  M. Gahr,et al.  IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA). , 2010, Clinical and experimental rheumatology.

[16]  R. Cimaz,et al.  Macrophage activation syndrome/hemophagocytic lymphohistiocytosis and Kawasaki disease , 2010, Pediatric blood & cancer.

[17]  E. Mellins,et al.  Macrophage activation syndrome: advances towards understanding pathogenesis , 2010, Current opinion in rheumatology.

[18]  N. Wulffraat,et al.  Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. , 2010, Rheumatology.

[19]  C. Wouters,et al.  Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. , 2009, Arthritis and rheumatism.

[20]  S. Ehl,et al.  Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. , 2009, American journal of human genetics.

[21]  J. Raemaekers,et al.  The role of rituximab in a case of EBV-related lymphoproliferative disease presenting with haemophagocytosis. , 2009, The Netherlands journal of medicine.

[22]  J. Huggins,et al.  Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin. , 2009, Clinical immunology.

[23]  J. Soep,et al.  Anakinra for Systemic Juvenile Arthritis: The Rocky Mountain Experience , 2009, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[24]  A. Ramanan,et al.  A case of macrophage activation syndrome successfully treated with anakinra , 2008, Nature Clinical Practice Rheumatology.

[25]  T. Kishimoto,et al.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial , 2008, The Lancet.

[26]  A. Filipovich,et al.  Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. , 2008, Arthritis and rheumatism.

[27]  E. Behrens.  Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell? , 2008, Autoimmunity reviews.

[28]  A. Fischer,et al.  Immunotherapy of Familial Hemophagocytic Lymphohistiocytosis With Antithymocyte Globulins: A Single-Center Retrospective Report of 38 Patients , 2007, Pediatrics.

[29]  D. Teachey,et al.  Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. , 2007, Journal of pediatric hematology/oncology.

[30]  R. Cron,et al.  Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. , 2007, The Journal of rheumatology.

[31]  A. Ramanan,et al.  The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. , 2007, Arthritis and rheumatism.

[32]  S. Prabhu,et al.  Macrophage activation syndrome: experience from a tertiary referral centre. , 2007, The Journal of the Association of Physicians of India.

[33]  M. Aricò,et al.  HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.

[34]  M. Piastra,et al.  First report of macrophage activation syndrome in hyperimmunoglobulinemia D with periodic fever syndrome. , 2007, Arthritis and rheumatism.

[35]  C. Lewis,et al.  Novel IL10 gene family associations with systemic juvenile idiopathic arthritis , 2006, Arthritis research & therapy.

[36]  R. Schneider,et al.  Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. , 2006, The Journal of pediatrics.

[37]  M. Robertson,et al.  Macrophage activation syndrome and other systemic inflammatory conditions after BMT , 2006, Bone Marrow Transplantation.

[38]  C. Dinarello,et al.  Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. , 2005, Blood.

[39]  A. Martini,et al.  Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. , 2005, The Journal of pediatrics.

[40]  H. Hennies,et al.  Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. , 2005, Human molecular genetics.

[41]  C. Wouters,et al.  Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. , 2005, Blood.

[42]  E. Giannini,et al.  Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome , 2004, Arthritis research & therapy.

[43]  N. Wulffraat,et al.  Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity , 2004, Annals of the rheumatic diseases.

[44]  P. Marrack,et al.  An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. , 2004, Blood.

[45]  R. Schneider,et al.  Macrophage activation syndrome: What's in a name! , 2003 .

[46]  A. Fischer,et al.  Munc13-4 Is Essential for Cytolytic Granules Fusion and Is Mutated in a Form of Familial Hemophagocytic Lymphohistiocytosis (FHL3) , 2003, Cell.

[47]  E. Goldmuntz,et al.  Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. , 2003, The Journal of pediatrics.

[48]  R. Schneider,et al.  Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. , 2003, The Journal of rheumatology.

[49]  K. Miyata,et al.  Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. , 2002, Arthritis and rheumatism.

[50]  B. Athreya.  Is macrophage activation syndrome a new entity? , 2002, Clinical and experimental rheumatology.

[51]  A. Prieur,et al.  Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. , 2001, Rheumatology.

[52]  S. Sawhney,et al.  Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders , 2001, Archives of disease in childhood.

[53]  D. Dickens,et al.  Etanercept in the treatment of macrophage activation syndrome. , 2001, The Journal of rheumatology.

[54]  A. Fischer,et al.  Perforin gene defects in familial hemophagocytic lymphohistiocytosis. , 1999, Science.

[55]  T. Mak,et al.  Homeostatic regulation of CD8+ T cells by perforin , 1999, European journal of immunology.

[56]  K. Sullivan,et al.  Defective Natural Killer Cell Function in Patients with Hemophagocytic Lymphohistiocytosis and in First Degree Relatives , 1998, Pediatric Research.

[57]  E. Jaffe,et al.  Contemporary classification of histiocytic disorders , 1997 .

[58]  E. Haddad,et al.  Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. , 1996, The Journal of pediatrics.

[59]  M. Passo,et al.  Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. , 1996, The Journal of pediatrics.

[60]  A. Martini,et al.  Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. , 1996, The Journal of pediatrics.

[61]  Prieur Am,et al.  Macrophage activation syndrome in rheumatic diseases in children , 1994 .

[62]  A. Prieur,et al.  Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. , 1993, Clinical and experimental rheumatology.

[63]  M. Siimes,et al.  Ferritinemia as an Indicator of Systemic Disease Activity in Children with Systemic Juvenile Rheumatoid Arthritis , 1986, Acta paediatrica Scandinavica.

[64]  C. Griscelli,et al.  Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. , 1985, The Journal of pediatrics.

[65]  A. Martini,et al.  Toward the Development of New Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis , 2012 .

[66]  M. Gahr,et al.  Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. , 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[67]  A. Ramanan,et al.  Profile of hemophagocytic lymphohistiocytosis in children in a tertiary care hospital in India , 2011, Indian pediatrics.

[68]  A. Filipovich.  Hemophagocytic lymphohistiocytosis (HLH) and related disorders. , 2009, Hematology. American Society of Hematology. Education Program.

[69]  E. Jaffe,et al.  Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. , 1997, Medical and pediatric oncology.